Pharming initiates Phase I study in ageing diseases

The Phase I trial that is now being conducted consists of a combined single and multiple dose escalating clinical study in healthy volunteers. By studying the pharmacokinetics and tolerability of Prodarsan and the effects of food intake on the absorption and elimination of the product, an oral dosing scheme will be determined that targets the pharmacological effective concentration range effectively.

It is expected that following a successful completion of this trial, the first clinical studies in patients will start later in 2008. Prodarsan is a defined combination of small molecules which is being developed to delay the progression of age-related diseases.